The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors.
2023-01-01 Buti, S.; Pecci, F.; Maffezzoli, M.; Giudice, G. C.; Cognigni, V.; Mazzaschi, G.; Cantini, L.; Santamaria, L.; Paoloni, F.; Berardi, R.; Perrone, F.
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study.
2023-01-01 Giudice, G. C.; Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M.
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling
2023-01-01 Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D’Agnelli, S.; Trentini, F.; Tamarozzi, P.; Moron Dalla Tor, L.; Verzè, M.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Buti, S.; Cosenza, A.; Quaini, F.; Sverzellati, N.; Tiseo, M.
Clinical relevance of first-line tyrosine kinase inhibitor (TKI) choice in metastatic renal cell carcinoma (mRCC) patients (pts) receiving second-line nivolumab (Meet-URO 15 study).
2023-01-01 Catalano, F.; Signori, A.; Sorarù, M.; Malgeri, A.; Di Napoli, M.; Caffo, O.; Vignani, F.; Cavo, A.; Roviello, G.; Prati, V.; Tudini, M.; Atzori, F.; Messina, M.; Damassi, A.; Morelli, F.; Prati, G.; Nolè, F.; Rescigno, P.; Buti, S.; Rebuzzi, S. E.
Adjusted Skeletal Muscle Index (aSMI) correlates with outcome in metastatic Renal Cancer Cell (mRCC) patients (pts) treated with first line (1L) immunotherapy (IT)
2023-01-01 D’Agostino, E.; Baldessari, C.; Farioli, F.; Agresti, G.; Basso, U.; Buti, S.; Favaretto, A.; Pettorelli, E.; Bacchelli, F.; Oltrecolli, M.; Pirola, M.; Roccabruna, S.; Pugliese, G.; Pipitone, S.; Vitale, M. G.; Fiocchi, F.; Dominici, M.; Sabbatini, R.
Use of concomitant proton pump inhibitors, statins, or metformin in patients treated with pembrolizumab for advanced urothelial carcinoma: data from the ARON-2 retrospective study.
2023-01-01 Maffezzoli, M.; Fiala, O.; Buti, S.; Massari, F.; Iacovelli, R.; Martignetti, A.; Morelli, F.; Mollica, V.; Porta, C.; Rizzo, M.; Rizzo, A.; Incorvaia, L.; Ciccarese, C.; Santoni, M.
Geographical differences in the management of metastatic de novo Renal Cell Carcinoma in the era of immune-combinations with a focus on the role of cytoreductive nephrectomy: an analysis from ARON- 1 Project.
2023-01-01 Rizzo, M.; Mollica, V.; Incorvaia, L.; Galli, L.; Merler, S.; Iacovelli, R.; Chiari, R.; Zucali, P. A.; Scagliarini, S.; De Giorgi, U.; Berardi, R.; Procopio, G.; Atzori, F.; Buti, S.; Bamias, A.; Battelli, N.; Grande, E.; Porta, C.; Massari, F.; Santoni, M.
Time to treatment failure (TTF) and treatment beyond progression (TBP) as survival outcome and therapeutic strategy of clinical benefit in pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab: a subanalysis of Meet-URO 15 study.
2023-01-01 Murianni, V.; Signori, A.; Buti, S.; Maruzzo, M.; De Giorgi, U.; Zucali, P. A.; Procopio, G.; Fratino, L.; Pipitone, S.; Mollica, V.; Lombardo, V.; Chiellino, S.; Galli, L.; Masini, C.; Naglieri, E.; Milella, M.; Ricotta, R.; Banna, G. L.; Cremante, M.; Rebuzzi, S. E.
Immunohistochemical (IHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: secondary analyses of the Meet-URO 18 study
2023-01-01 Rebuzzi, S. E.; Brunelli, M.; Signori, A.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Galli, L.; Spada, M.; Milella, M.; Masini, C.; Cavo, A.; Vignani, F.; Catalano, F.; Maffezzoli, M.; Rescigno, P.; Banna, G. L.; Basso, U.; Buti, S.; Fornarini, G.
Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). The Tide-A study
2023-01-01 Iacovelli, R.; Ciccarese, C.; Bersanelli, M.; Zucali, P. A.; Fantinel, E.; Bimbatti, D.; Verzoni, E.; Accettura, C.; Bonomi, L.; Buttigliero, C.; Fornarini, G.; Pipitone, S.; Atzori, F.; Masini, C.; Massari, F.; Primi, F.; Buti, S.; Perrino, M.; Pafumi, S.; Tortora, G.
Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)
2024-01-01 Bracarda, Sergio; Antonuzzo, Lorenzo; Maruzzo, Marco; Santini, Daniele; Tambaro, Rosa; Buti, Sebastiano; Carrozza, Francesco; Calabrò, Fabio; Di Lorenzo, Giuseppe; Fornarini, Giuseppe; Iacovelli, Roberto; Cullurà, Daniela; Messina, Carlo; Cerbone, Linda; Fazzi, Gennaro; Venturini, Filippo; Colasanto, Raffaele; Necchi, Andrea; De Giorgi, Ugo
International multicenter real-world registry for patients with metastatic renal cell carcinoma: Meet-URO 33 study (REGAL study)
2024-01-01 Rebuzzi, Sara Elena; Fornarini, Giuseppe; Signori, Alessio; Buti, Sebastiano; Procopio, Giuseppe; De Giorgi, Ugo; Pignata, Sandro; Naglieri, Emanuele; Maruzzo, Marco; Banna, Giuseppe Luigi; Rescigno, Pasquale; Messina, Carlo; Nasso, Cecilia; Murianni, Veronica; Cremante, Malvina; Damassi, Alessandra; Catalano, Fabio; Mattana, Alvise; Basso, Umberto; Bimbatti, Davide; Null, Null
Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study)
2024-01-01 Ciccarese, Chiara; Verzoni, Elena; Bimbatti, Davide; Buti, Sebastiano; Calabrò, Fabio; Galli, Luca; Scagliarini, Sarah; Fornarini, Giuseppe; Baldessari, Cinzia; Bilancia, Domenico; Facchini, Gaetano; Cattrini, Carlo; Masini, Cristina; Giganti, Maria Olga; Scandurra, Giuseppa; Nole, Franco; Berruti, Alfredo; Milella, Michele; Antonuzzo, Lorenzo; Iacovelli, Roberto
Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31)
2024-01-01 Stellato, Marco; Procopio, Giuseppe; Romei, Chiara; Colantonio, Sara; Cattaneo, Laura; Claps, Melanie; Guadalupi, Valentina; Sepe, Pierangela; Basso, Umberto; Buti, Sebastiano; Fornarini, Giuseppe; Vignani, Francesca; Fratino, Lucia; Iacovelli, Roberto; Nole, Franco; Di Napoli, Marilena; Zucali, Paolo Andrea; De Braud, Filippo G.; Del Re, Marzia
Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study
2024-01-01 Iacovelli, Roberto; Fantinel, Emanuela; Bimbatti, Davide; Buti, Sebastiano; Bonomi, Lucia; Rizzo, Mimma; Accettura, Caterina; Buttigliero, Consuelo; Massari, Francesco; Santoni, Matteo; Zucali, Paolo Andrea; Zanardi, Elisa; Mosca, Alessandra; Primi, Francesca; Spina, Francesco; Procopio, Giuseppe; Bracarda, Sergio; Calabrò, Fabio; Antonuzzo, Lorenzo; Ciccarese, Chiara
First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial
2022-01-01 Iacovelli, R; Ciccarese, C; Brunelli, M; Battelli, N; Buttigliero, C; Caserta, C; Buti, S; Santini, D; Naglieri, E; Galli, L; Verri, E; Ermacora, P; Milella, M; Masini, C; Aprile, G; Milesi, L; Spina, F; Rizzo, M; Sperduti, I; Fornarini, G; Tortora, G
Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study
2024-01-01 Mollica, V.; Massari, F.; Fiala, O.; Kucharz, J.; Molina-Cerrillo, J.; Seront, E.; Bourlon, M. T.; Pichler, R.; Myint, Z. W.; Kanesvaran, R.; Marchetti, A.; Rosellini, M.; Rescigno, P.; de Liano, A. G.; Zakopoulou, R.; Buti, S.; Porta, C.; Grande, E.; Santoni, M.
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study
2023-01-01 Ciccarese, C; Buti, S; Roberto, M; Calabrò, F; Masini, C; Massari, F; Cannella, M; Mazzaschi, G; Astore, S; Di Girolamo, S; Panebianco, M; Mollica, ; Granitto, A; Fiorentino, ; Pierconti, F; Martini, M; Porta, C; Tortora, G; Iacovelli, R
1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023-01-01 Massari, F.; Pulido, E. Grande; Bamias, A.; Iacovelli, R.; Cerrillo, J. Molina; Procopio, G.; Fiala, O.; Myint, Z. W.; De Giorgi, U. F. F.; Buchler, T.; Santini, D.; Büttner, T.; Roviello, G.; Pichler, M.; Bourlon de los Rios, M. T.; Rizzo, A.; Monteiro, F. S. M.; Buti, S.; Porta, C. G.; Santoni, M.
1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)
2023-01-01 Verzoni, E.; Procopio, G.; Bottiglieri, A.; Stellato, M.; Rametta, A.; Zucali, P. A.; Perrucci, B.; G. fornarini, Null; Buti, S.; Maruzzo, M.; Cova, A.; Squarcina, P.; Lalli, L.; Mereu, A.; Cerioli, N.; Agnelli, L.; Todoerti, K.; Busico, A.; Rivoltini, L.; Huber, V.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. | 1-gen-2023 | Buti, S.; Pecci, F.; Maffezzoli, M.; Giudice, G. C.; Cognigni, V.; Mazzaschi, G.; Cantini, L.; Santamaria, L.; Paoloni, F.; Berardi, R.; Perrone, F. | |
| Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. | 1-gen-2023 | Giudice, G. C.; Cortellini, A.; Leonetti, A.; Parisi, A.; Tiseo, M.; Bordi, P.; Michiara, M.; Bui, S.; Cosenza, A.; Ferri, L.; Testi, I.; Vincenzi, B.; Santo, V.; Ricozzi, V.; Sgargi, P.; Zustovich, F.; Stucci, L. S.; Santini, D.; Buti, S.; Bersanelli, M. | |
| Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling | 1-gen-2023 | Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D’Agnelli, S.; Trentini, F.; Tamarozzi, P.; Moron Dalla Tor, L.; Verzè, M.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Buti, S.; Cosenza, A.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| Clinical relevance of first-line tyrosine kinase inhibitor (TKI) choice in metastatic renal cell carcinoma (mRCC) patients (pts) receiving second-line nivolumab (Meet-URO 15 study). | 1-gen-2023 | Catalano, F.; Signori, A.; Sorarù, M.; Malgeri, A.; Di Napoli, M.; Caffo, O.; Vignani, F.; Cavo, A.; Roviello, G.; Prati, V.; Tudini, M.; Atzori, F.; Messina, M.; Damassi, A.; Morelli, F.; Prati, G.; Nolè, F.; Rescigno, P.; Buti, S.; Rebuzzi, S. E. | |
| Adjusted Skeletal Muscle Index (aSMI) correlates with outcome in metastatic Renal Cancer Cell (mRCC) patients (pts) treated with first line (1L) immunotherapy (IT) | 1-gen-2023 | D’Agostino, E.; Baldessari, C.; Farioli, F.; Agresti, G.; Basso, U.; Buti, S.; Favaretto, A.; Pettorelli, E.; Bacchelli, F.; Oltrecolli, M.; Pirola, M.; Roccabruna, S.; Pugliese, G.; Pipitone, S.; Vitale, M. G.; Fiocchi, F.; Dominici, M.; Sabbatini, R. | |
| Use of concomitant proton pump inhibitors, statins, or metformin in patients treated with pembrolizumab for advanced urothelial carcinoma: data from the ARON-2 retrospective study. | 1-gen-2023 | Maffezzoli, M.; Fiala, O.; Buti, S.; Massari, F.; Iacovelli, R.; Martignetti, A.; Morelli, F.; Mollica, V.; Porta, C.; Rizzo, M.; Rizzo, A.; Incorvaia, L.; Ciccarese, C.; Santoni, M. | |
| Geographical differences in the management of metastatic de novo Renal Cell Carcinoma in the era of immune-combinations with a focus on the role of cytoreductive nephrectomy: an analysis from ARON- 1 Project. | 1-gen-2023 | Rizzo, M.; Mollica, V.; Incorvaia, L.; Galli, L.; Merler, S.; Iacovelli, R.; Chiari, R.; Zucali, P. A.; Scagliarini, S.; De Giorgi, U.; Berardi, R.; Procopio, G.; Atzori, F.; Buti, S.; Bamias, A.; Battelli, N.; Grande, E.; Porta, C.; Massari, F.; Santoni, M. | |
| Time to treatment failure (TTF) and treatment beyond progression (TBP) as survival outcome and therapeutic strategy of clinical benefit in pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab: a subanalysis of Meet-URO 15 study. | 1-gen-2023 | Murianni, V.; Signori, A.; Buti, S.; Maruzzo, M.; De Giorgi, U.; Zucali, P. A.; Procopio, G.; Fratino, L.; Pipitone, S.; Mollica, V.; Lombardo, V.; Chiellino, S.; Galli, L.; Masini, C.; Naglieri, E.; Milella, M.; Ricotta, R.; Banna, G. L.; Cremante, M.; Rebuzzi, S. E. | |
| Immunohistochemical (IHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: secondary analyses of the Meet-URO 18 study | 1-gen-2023 | Rebuzzi, S. E.; Brunelli, M.; Signori, A.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Galli, L.; Spada, M.; Milella, M.; Masini, C.; Cavo, A.; Vignani, F.; Catalano, F.; Maffezzoli, M.; Rescigno, P.; Banna, G. L.; Basso, U.; Buti, S.; Fornarini, G. | |
| Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). The Tide-A study | 1-gen-2023 | Iacovelli, R.; Ciccarese, C.; Bersanelli, M.; Zucali, P. A.; Fantinel, E.; Bimbatti, D.; Verzoni, E.; Accettura, C.; Bonomi, L.; Buttigliero, C.; Fornarini, G.; Pipitone, S.; Atzori, F.; Masini, C.; Massari, F.; Primi, F.; Buti, S.; Perrino, M.; Pafumi, S.; Tortora, G. | |
| Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) | 1-gen-2024 | Bracarda, Sergio; Antonuzzo, Lorenzo; Maruzzo, Marco; Santini, Daniele; Tambaro, Rosa; Buti, Sebastiano; Carrozza, Francesco; Calabrò, Fabio; Di Lorenzo, Giuseppe; Fornarini, Giuseppe; Iacovelli, Roberto; Cullurà, Daniela; Messina, Carlo; Cerbone, Linda; Fazzi, Gennaro; Venturini, Filippo; Colasanto, Raffaele; Necchi, Andrea; De Giorgi, Ugo | |
| International multicenter real-world registry for patients with metastatic renal cell carcinoma: Meet-URO 33 study (REGAL study) | 1-gen-2024 | Rebuzzi, Sara Elena; Fornarini, Giuseppe; Signori, Alessio; Buti, Sebastiano; Procopio, Giuseppe; De Giorgi, Ugo; Pignata, Sandro; Naglieri, Emanuele; Maruzzo, Marco; Banna, Giuseppe Luigi; Rescigno, Pasquale; Messina, Carlo; Nasso, Cecilia; Murianni, Veronica; Cremante, Malvina; Damassi, Alessandra; Catalano, Fabio; Mattana, Alvise; Basso, Umberto; Bimbatti, Davide; Null, Null | |
| Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study) | 1-gen-2024 | Ciccarese, Chiara; Verzoni, Elena; Bimbatti, Davide; Buti, Sebastiano; Calabrò, Fabio; Galli, Luca; Scagliarini, Sarah; Fornarini, Giuseppe; Baldessari, Cinzia; Bilancia, Domenico; Facchini, Gaetano; Cattrini, Carlo; Masini, Cristina; Giganti, Maria Olga; Scandurra, Giuseppa; Nole, Franco; Berruti, Alfredo; Milella, Michele; Antonuzzo, Lorenzo; Iacovelli, Roberto | |
| Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31) | 1-gen-2024 | Stellato, Marco; Procopio, Giuseppe; Romei, Chiara; Colantonio, Sara; Cattaneo, Laura; Claps, Melanie; Guadalupi, Valentina; Sepe, Pierangela; Basso, Umberto; Buti, Sebastiano; Fornarini, Giuseppe; Vignani, Francesca; Fratino, Lucia; Iacovelli, Roberto; Nole, Franco; Di Napoli, Marilena; Zucali, Paolo Andrea; De Braud, Filippo G.; Del Re, Marzia | |
| Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study | 1-gen-2024 | Iacovelli, Roberto; Fantinel, Emanuela; Bimbatti, Davide; Buti, Sebastiano; Bonomi, Lucia; Rizzo, Mimma; Accettura, Caterina; Buttigliero, Consuelo; Massari, Francesco; Santoni, Matteo; Zucali, Paolo Andrea; Zanardi, Elisa; Mosca, Alessandra; Primi, Francesca; Spina, Francesco; Procopio, Giuseppe; Bracarda, Sergio; Calabrò, Fabio; Antonuzzo, Lorenzo; Ciccarese, Chiara | |
| First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial | 1-gen-2022 | Iacovelli, R; Ciccarese, C; Brunelli, M; Battelli, N; Buttigliero, C; Caserta, C; Buti, S; Santini, D; Naglieri, E; Galli, L; Verri, E; Ermacora, P; Milella, M; Masini, C; Aprile, G; Milesi, L; Spina, F; Rizzo, M; Sperduti, I; Fornarini, G; Tortora, G | |
| Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study | 1-gen-2024 | Mollica, V.; Massari, F.; Fiala, O.; Kucharz, J.; Molina-Cerrillo, J.; Seront, E.; Bourlon, M. T.; Pichler, R.; Myint, Z. W.; Kanesvaran, R.; Marchetti, A.; Rosellini, M.; Rescigno, P.; de Liano, A. G.; Zakopoulou, R.; Buti, S.; Porta, C.; Grande, E.; Santoni, M. | |
| Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study | 1-gen-2023 | Ciccarese, C; Buti, S; Roberto, M; Calabrò, F; Masini, C; Massari, F; Cannella, M; Mazzaschi, G; Astore, S; Di Girolamo, S; Panebianco, M; Mollica, ; Granitto, A; Fiorentino, ; Pierconti, F; Martini, M; Porta, C; Tortora, G; Iacovelli, R | |
| 1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations | 1-gen-2023 | Massari, F.; Pulido, E. Grande; Bamias, A.; Iacovelli, R.; Cerrillo, J. Molina; Procopio, G.; Fiala, O.; Myint, Z. W.; De Giorgi, U. F. F.; Buchler, T.; Santini, D.; Büttner, T.; Roviello, G.; Pichler, M.; Bourlon de los Rios, M. T.; Rizzo, A.; Monteiro, F. S. M.; Buti, S.; Porta, C. G.; Santoni, M. | |
| 1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8) | 1-gen-2023 | Verzoni, E.; Procopio, G.; Bottiglieri, A.; Stellato, M.; Rametta, A.; Zucali, P. A.; Perrucci, B.; G. fornarini, Null; Buti, S.; Maruzzo, M.; Cova, A.; Squarcina, P.; Lalli, L.; Mereu, A.; Cerioli, N.; Agnelli, L.; Todoerti, K.; Busico, A.; Rivoltini, L.; Huber, V. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Articolo su rivista1822
Data di pubblicazione
- 2020 - 2026211
- 2010 - 2019847
- 2000 - 2009537
- 1990 - 1999175
- 1980 - 198951
- 1979 - 19791
Editore
- ELSEVIER25
- Elsevier17
- SAGE PUBLICATIONS LTD17
- DIKE GIURIDICA15
- ASCO pubs11
- ELSEVIER IRELAND LTD7
- ASCO6
- ELSEVIER SCIENCE INC5
- SAGE5
- SPRINGERNATURE4
Rivista
- DIGESTIVE AND LIVER DISEASE101
- GASTROENTEROLOGY100
- ANNALS OF ONCOLOGY94
- BLOOD91
- HAEMATOLOGICA59
- JOURNAL OF CLINICAL ONCOLOGY58
- NEUROLOGICAL SCIENCES47
- UNITED EUROPEAN GASTROENTEROLOGY ...46
- ANNALS OF THE RHEUMATIC DISEASES36
- EPILEPSIA26
Keyword
- Helicobacter pylori10
- epilepsy9
- sclerosi sistemica6
- Bioengineering5
- Gastroenterology5
- HCV5
- temporal lobe epilepsy5
- UV5
- GERD4
- Lungs4
Lingua
- eng970
- ita178
- fre1
Accesso al fulltext
- no fulltext1790
- reserved26
- open6